Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.

Kadowaki T, Heftdal LD, Ko HJ, Overvad M, Shimomura I, Thamattoor UK, Kim KK

JAMA internal medicine1 Oct 2025Cited by 16 (Europe PMC)

PMID40758358PMCIDPMC12322823DOI10.1001/jamainternmed.2025.3599PepBankPUB-40758358

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, oral semaglutide 50 mg reduced body weight by 14.3% versus 1.3% with placebo over 68 weeks.
In plain wordsIn East Asian adults with overweight or obesity, people on oral semaglutide lost far more body weight than people on placebo over 68 weeks.
Peptide
Semaglutide
Outcome
DecreasePercentage change in body weight
Study
n = 201
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
50 mg · oral · 68 weeksAs given in this study (human).
Measurements
Mean body weight change
−14.3%
semaglutide
Mean body weight change
−1.3%
placebo
Estimated treatment difference
−13.07 percentage points
semaglutide vs placebo
Source sentences
Summary
The mean (SEM) percentage change in body weight was -14.3% (0.8) with semaglutide vs -1.3% (1.1) with placebo (estimated treatment difference, -13.07 percentage points; 95% CI, -15.61 to -10.52; P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
The OASIS 2 trial was a 68-week (plus 7 weeks of follow-up) multicenter, double-blind, placebo-controlled phase 3a randomized clinical trial conducted from November 2021 to September 2023 in Japan and South Korea.
Summary · context
Participants were assigned 2:1 to once-daily oral semaglutide, 50 mg, or placebo, plus lifestyle recommendations, for 68 weeks.
Report a problemFND-4075835801
02HumanRandomized controlled trialEfficacy outcome
In East Asian adults with overweight or obesity, more participants had a body weight reduction of 5% or more with oral semaglutide 50 mg (84.3%) than with placebo (17.2%).
In plain wordsIn East Asian adults with overweight or obesity, many more people lost at least 5% of body weight on oral semaglutide than on placebo.
Peptide
Semaglutide
Outcome
IncreaseProportion with body weight reduction of 5% or more
Study
n = 191
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
50 mg · oral · 68 weeksAs given in this study (human).
Measurements
Proportion with 5% or greater weight reduction
84.3%
semaglutide
Proportion with 5% or greater weight reduction
17.2%
placebo
Odds ratio
23
semaglutide vs placebo
Source sentences
Summary
More participants had 5% or greater body weight reductions with semaglutide vs placebo (107 of 127 [84.3%] vs 11 of 64 [17.2%]; odds ratio, 23.00; 95% CI, 10.28-51.42; P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
The OASIS 2 trial was a 68-week (plus 7 weeks of follow-up) multicenter, double-blind, placebo-controlled phase 3a randomized clinical trial conducted from November 2021 to September 2023 in Japan and South Korea.
Summary · context
Participants were assigned 2:1 to once-daily oral semaglutide, 50 mg, or placebo, plus lifestyle recommendations, for 68 weeks.
Report a problemFND-4075835802
03HumanRandomized controlled trialSafety outcome
In East Asian adults with overweight or obesity, gastrointestinal adverse events were reported by 63.4% with oral semaglutide 50 mg and 34.8% with placebo.
In plain wordsIn East Asian adults with overweight or obesity, stomach and gut side effects were more common with oral semaglutide than with placebo.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 200
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
50 mg · oral · 68 weeksAs given in this study (human).
Measurements
Participants with GI adverse events
63.4%
semaglutide
Participants with GI adverse events
34.8%
placebo
Source sentences
Summary
Gastrointestinal tract adverse events were reported by 85 of 134 participants (63.4%) with semaglutide and 23 of 66 with placebo (34.8%).
2 context sentences(design, population, supporting numbers)
Summary · context
The OASIS 2 trial was a 68-week (plus 7 weeks of follow-up) multicenter, double-blind, placebo-controlled phase 3a randomized clinical trial conducted from November 2021 to September 2023 in Japan and South Korea.
Summary · context
Participants were assigned 2:1 to once-daily oral semaglutide, 50 mg, or placebo, plus lifestyle recommendations, for 68 weeks.
Report a problemFND-4075835803
04HumanRandomized controlled trialSafety outcome
In East Asian adults with overweight or obesity, adverse events led to treatment discontinuation in 4.5% of participants on oral semaglutide 50 mg.
In plain wordsIn East Asian adults with overweight or obesity, 4.5% of people on oral semaglutide stopped treatment because of side effects.
Peptide
Semaglutide
Outcome
Not applicableAdverse events leading to discontinuation
Study
n = 134
Outcome group
Adverse events · Whole body
Studied dose
50 mg · oral · 68 weeksAs given in this study (human).
Measurements
Discontinuation due to adverse events
4.5%
semaglutide arm
Source sentences
Summary
Adverse events led to treatment discontinuation in 6 of 134 participants (4.5%) in the semaglutide arm.
2 context sentences(design, population, supporting numbers)
Summary · context
The OASIS 2 trial was a 68-week (plus 7 weeks of follow-up) multicenter, double-blind, placebo-controlled phase 3a randomized clinical trial conducted from November 2021 to September 2023 in Japan and South Korea.
Summary · context
Participants were assigned 2:1 to once-daily oral semaglutide, 50 mg, or placebo, plus lifestyle recommendations, for 68 weeks.
Report a problemFND-4075835804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT05132088

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity

Novo Nordisk A/Sn = 20116 Nov 2021 to 1 Sept 2023

Overweight and Obesity

Trial page ClinicalTrials.govUpdated 14 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.